Smartnuclide Biopharma
Clinical trials sponsored by Smartnuclide Biopharma, explained in plain language.
-
New radiation drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New scan agent could spot pancreatic cancer more clearly
Diagnosis Recruiting nowThis early-stage study is testing a new contrast agent called 68Ga-NODAGA-SNA014, which targets a protein (CLDN18.2) found on some pancreatic cancer cells. The agent is used with PET/CT scans to see if it can safely and accurately highlight tumors. The study involves 12 adults wi…
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC